Pinney Associates, Inc.

What Pinney Associates, Inc. does

Pinney Associates, Inc. is a Bethesda, Maryland-based scientific and regulatory consulting firm founded in 1995 that serves pharmaceutical, consumer healthcare, dietary supplement, and tobacco/alternative nicotine product companies. The firm operates as a private, for-profit professional services organization with a reported headcount in the 11-50 range, delivering advisory work through senior scientific and regulatory experts in a sales-led B2B consulting engagement model.

The firm's product portfolio is organized into four interconnected practice areas plus an embedded data analysis function: Prescription Medicines Consulting (CNS-active drugs, psychedelics, cannabinoids, abuse potential assessment, REMS program development), OTC Products Consulting (Rx-to-OTC switch strategy and consumer healthcare brand support), Dietary Ingredients and Supplements Consulting (science-based regulatory pathways), and Tobacco Harm Minimization Services (harm reduction research and policy). The data analysis team supports all practice areas with statistical analysis, simulation modeling, and visualization to address regulatory and policy questions. Underlying expertise spans FDA 2017 abuse potential guidance, behavioral science, clinical trial design, and CSA scheduling recommendations.

Pinney generates revenue through direct consulting engagements billed on a professional services basis, with no publicly disclosed pricing. The firm markets primarily through scientific publications, position papers, conference participation, webinars, and its corporate website and LinkedIn presence. The company has not raised institutional funding, has no parent company, and is independently owned and operated by its senior leadership team. Notable regulatory milestones include the firm's role in supporting FDA approvals of OTC Opill, the first OTC oral contraceptive in the United States (July 13, 2023), and OTC RiVive, the first OTC naloxone nasal spray (July 28, 2023).

Name

Pinney Associates, Inc.

Legal name

Pinney Associates, Inc.

Website

https://pinneyassociates.com

Company type

Private

Founded year

1995

Operating status

Operating

Headcount range

11–50 employees

Short description

Pinney Associates is a Bethesda-based scientific and regulatory consulting firm advising pharmaceutical and consumer healthcare companies on FDA pathways, including Rx-to-OTC switches, abuse liability assessment, psychedelic drug development, dietary supplement regulation, and tobacco harm minimization.

Ownership category

akta.pro rank

Headquarters

HQ city

Bethesda

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Regulatory and Scientific Consulting: Professional consulting services providing regulatory strategy, FDA guidance, abuse liability assessment, clinical development support, and policy counsel to pharmaceutical and consumer healthcare companies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Pinney Associates provides scientific and regulatory consulting services to pharmaceutical and consumer healthcare companies across four practice areas: prescription medicines (CNS-active drugs, psychedelics, cannabinoids, abuse liability), OTC products (Rx-to-OTC switch strategy), dietary ingredients and supplements (regulatory pathways), and tobacco harm minimization. A dedicated data analysis team supports these practices with statistical modeling and regulatory data analysis.

Product overview

Pinney Associates offers a unified portfolio of consulting services focused on pharmaceutical and consumer healthcare regulatory affairs. The firm provides expert guidance across four interconnected practice areas: Prescription Medicines Consulting (specializing in CNS-active drugs, psychedelics, and cannabinoids), OTC Products Consulting (Rx-to-OTC switch strategy), Dietary Ingredients & Supplements Consulting (regulatory pathways), and Tobacco Harm Minimization Services (harm reduction policy). Their Data Analysis team supports all practice areas with regulatory and policy insights. The company is particularly recognized for its leadership role in achieving FDA approval of over-the-counter Opill (first OTC oral contraceptive) and OTC RiVive (naloxone nasal spray).

Differentiator

Problem solved

Functional benefit

Products and services

• Prescription Medicines Consulting Consulting services for pharmaceutical companies developing CNS-active drugs, including traditional pharmaceuticals, psychedelics, and cannabinoids, with emphasis on abuse potential assessment, clinical trial design, scheduling strategy, and regulatory guidance.
• OTC Products Consulting Rx-to-OTC switch consulting and support for marketed consumer healthcare brands, including regulatory pathway planning, FDA approval strategy, behavioral research, label comprehension studies, and commercial planning.
• Dietary Ingredients & Supplements Consulting Consulting services for companies developing dietary ingredients and supplements, including science-based regulatory pathway mapping, safety and tolerability studies, and FDA oversight compliance.
• Tobacco Harm Minimization Services Advisory services for companies developing alternative nicotine products and tobacco harm minimization solutions, including harm reduction strategy, e-cigarette evaluation, smoking cessation evidence development, and public health policy counsel.
• Data Analysis Services Specialized data analysis services using statistical methodologies, data management, and simulation modeling to generate insights and answer regulatory and policy questions for clients.

Quantifiable outcome

• Achieved FDA approval for Opill - first OTC oral contraceptive in the US (July 13, 2023)
• +3 more outcomes

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Others

• PinneyAssociates.com / Pinney Associates (already covered): Duplicate reference excluded from final peer list.
• Consumer Healthcare Products Association (CHPA): Industry trade association representing OTC manufacturers and distributors, including on Rx-to-OTC switch policy. Not a direct competitor, but Pinney is an active participant in CHPA conferences and ecosystem, and CHPA members are potential clients for Pinney's OTC practice.

Broad incumbents

• Parexel International: Large CRO offering regulatory consulting, clinical development, and commercialization services to pharma and biotech. Overlaps Pinney's prescription medicine consulting and FDA strategy work but at substantially greater scale and with global delivery.
• McKinsey & Company (Pharma Practice): Top-tier management consultancy with a global pharma and medical products practice covering regulatory strategy, R&D, and commercialization. Adjacent competitor for senior-level regulatory and strategic advisory engagements, particularly with large pharma clients.
• IQVIA: Global CRO and life sciences consulting leader with deep regulatory affairs, RWE, and commercialization capabilities. Overlaps Pinney's pharma regulatory advisory work but as part of a much broader services portfolio; competes primarily on enterprise-scale mandates.
• Covington & Burling (FDA/Regulatory Practice): Leading law firm with one of the deepest FDA regulatory and drug law practices, serving pharma, consumer health, and dietary supplement clients. Competes with Pinney on regulatory strategy matters, especially where legal counsel is bundled with scientific advisory.

Direct peers

• Worldwide Clinical Trials: Mid-size CRO with strong CNS and abuse liability clinical research capabilities, overlapping Pinney's CNS-active drug development and abuse potential assessment work. Direct peer in CNS clinical and regulatory consulting, though larger and broader in service offering.
• Charles River Associates: Life sciences consulting practice providing regulatory, economic, and strategic advisory to pharma clients. Comparable in regulatory and policy advisory focus, with a stronger emphasis on economics and litigation support versus Pinney's abuse liability and OTC switch specialization.
• PharmaLex (formerly NDA Group): Global regulatory affairs and scientific consulting firm serving pharma and consumer health clients on FDA/EMA strategy, CMC, and product development. Highly comparable to Pinney in service mix, with greater geographic reach but less US-focused Rx-to-OTC switch specialization.
• Lachman Consultants: US-based pharmaceutical regulatory and compliance consulting firm focused on FDA matters, GMP, and product development strategy. Comparable in size and US-centric regulatory focus, though Pinney's OTC switch and abuse liability practices are distinct differentiators.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/pinney-associates

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pinney Associates, Inc.